Minerva Neurosciences | NERV - Equity Capital And Reserves


Minerva Neurosciences reported $-140.75M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Adma Biologics USD 390.32M 86.99M Mar/2026
ALKERMES USD 1.75B 67.76M Mar/2026
Alterity Therapeutics Limited AUD 36.21M 18.58M Dec/2025
AstraZeneca USD 47.33B 1.33B Mar/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Cipla INR 344.32B 15.13B Mar/2026
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 102.73M 58.9M Dec/2025
CSL USD 18.66B 2.75B Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Esperion Therapeutics USD -307.93M 5.97M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Grifols EUR 6.21B 133.12M Dec/2025
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
J&J USD 81.19B 358M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Novavax USD -144.76M 17.01M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 72.81B 1.1B Mar/2026
Takeda JPY 7.77T 129.5B Mar/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025